Member Info for BurtonD

Https://ecrminerals.com/wp-content/uploads/2025/05/ECR-Presentation-Nov-2024.pdf

The team have returned from @atscommunity the American Thoracic Society (ATS) International Conference in San Francisco.

Check out their key take aways from the conference:

✅Major advancements in gene therapies and personalized medicine for diseases like cystic fibrosis were showcased

✅Good progress on propellant studies facilitating the change over to low carbon inhalers

✅Digital Health and emerging tech on cutting-edge tools like a digital incentive spirometer to improve patient adherence

✅Great meetings with pharma, biotech and academia

...£5m proposed share buy back due of course. 70p anyone?

The POLB CEO spoke with @proactive_UK to discuss the latest updates from #POLB

🎯 FDA awards Orphan Drug Designation for POLB 001 - providing clinical development & commercialisation benefits and strengthening its commercial appeal for prospective partners

🔬 Strong indications from Big Pharma will provide the necessary bispecific antibody, free of charge, to support our proposed Phase 2a trial

🚀 Conditionally raised £4.865 million in an oversubscribed placing, plus subscription and BookBuild retail offer

👉 Multiple near term value inflection points

Watch full interview here:

Watch here: https://www.youtube.com/watch?v=DmC5uo0N9-w

Https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor

Good morning,

I hope all is well and you may have seen the exciting Poolbeg Pharma announcement that the FDA has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (CRS).

https://www.londonstockexchange.com/news-article/POLB/fda-orphan-drug-designation-granted-for-polb-001/17054590

The FDA grants orphan status to support the development for rare disorders affecting

ROAD AGM statement – market hasn’t read paragraph 11 on this – 14.75mln is a lot of fire power to buy back!!!!

THAT the Company is generally and unconditionally authorised for the purposes of section 701 of

the Act to make one or more market purchases (within the meaning of section 693(4) of the Act)

of its own ordinary shares on such terms and in such manner as the Directors may from time to

time determine, but subject to the following provisions:

(a) the maximum aggregate number of ordinary shares authorised to be purchased is 14,367,780;

(b) the minimum price (excluding expenses) which may be paid for each ordinary share is

£0.00860675675675676; and

(c) the maximum price (excluding expenses) which may be paid for each ordinary share is the

higher of:

(i) 105 per cent. of the average market value of the Company’s ordinary shares for the five

business days prior to the day on which that ordinary share is contracted to be purchased;

and

(ii) the higher of the price of the last independent trade of and the highest current

independent bid for the Company’s ordinary shares on the AIM market of the London

Stock Exchange at the time that ordinary share is contracted to be purchased,

Good morning,

I hope all is well and we are please to share the result of the upsized and oversubscribed BookBuild Offer: https://www.londonstockexchange.com/news-article/POLB/result-of-upsized-oversubscribed-bookbuild-offer/17051414

· Conditionally raised gross proceeds of £150,000 from the upsized and oversubscribed BookBuild Offer

· Total gross proceeds conditionally raised pursuant to the Fundraising therefore increased to £4.865 million

· Use of net proceeds from the Fundraising:

o Phase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS)

o Oral GLP-1 proof-of-concept clinical trial

o Cash runway extended through to 2027

It is a tremendous endorsement for the Company and the potential of both our POLB 001 and Oral GLP-1 programmes that both new and existing investors have supported us so robustly, despite very challenging conditions in the biopharma financing market. We are grateful for their support and look forward to putting their investment to work in the clinic and moving these programmes forward through upcoming critical value inflection points.

The Fundraise is subject to, amongst other things, the passing of the Resolutions at the General Meeting scheduled for 23 June 2025.

Https://www.londonstockexchange.com/news-article/LEX/drilling-commences-at-the-jennings-pioneer/17051391

“…the company has secured new funding, shone further light on the zebediela project’s potential scope, and passed regulatory requirements that have taken it to the threshold of drilling…”

**********************************/2025/05/uru-metals-ltd-2/

Https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/w0kjl6r

Https://www.londonstockexchange.com/news-article/BLOE/final-results/17049020

the @tmsreach team catch up with egt cfo jack kelly and discuss carbon credits, tariffs and revenue generating assets.

**********************************/2025/05/15208/

Geophys has identified high priority drill targets at its flagship project in South Africa.

https://www.londonstockexchange.com/news-article/URU/zeb-nickel-identifies-high-priority-drill-targets/17046543

We are pleased to announce that our #LEX Chief Executive Officer, Bernard Olivier, will provide a live presentation and Q&A via @InvestorMeetCo

📆Wednesday, 4th June

⏰13:00 BST.

Register below ⤵️

investormeetcompany.com/lexington-gold…

Lexington Gold (AIM: LEX; OTCQB: LEXLF), the gold exploration and development company with projects in South Africa and the USA, is pleased to announce that it has received its final Section 11 Ministerial Consent from the South African Department of Mineral Resources and Energy ("DMRE") in connection with its acquisition of its 74% owned subsidiary White Rivers Exploration Proprietary Limited ("WRE") ("Ministerial Consent").

Further to the Company's announcements on 15 May 2023 and 7 September 2023, the granting of Ministerial Consent is a milestone event which triggers the issue of 20,645,161 new common shares ("Deferred Consideration Shares") to settle £1.28 million deferred consideration, calculated at an issue price of 6.20 pence per share ("Issue Price"). This relates to the assignment to the Company of WRE loans, comprising Mark Creasy's loans with a face value of ZAR197.0 million (approximately £8.50 million) and US$2.0 million (approximately £1.59m) made by Sunswell Holdings Pty Ltd ("WRE Loan Assignments").

https://www.londonstockexchange.com/news-article/LEX/ministerial-consent-received-for-wre-acquisition/17044220

Almost laughable....

You comment you get slaughtered. You don't comment you get slaughtered!

Nothing more from me on here. Over and out...

Https://www.linkedin.com/feed/update/urn:li:activity:7329104500558807040

Https://hvivo.com/wp-content/uploads/2025/04/hVIVO-FY24-Results-Presentation.pdf

Https://wp-poolbeg-pharma-2021.s3.eu-west-2.amazonaws.com/media/2025/05/Poolbeg-Pharma-Presentation-May-2025.pdf